Growth Hormone Treatment in
Children with Malignant Cranial
Tumours in KIGS
Michael B Ranke and David A Price
KIGS 10 Year Book, 1999
(1/6)
Auxological characteristics of KIGS patients
with CNS tumours near the pituitary region
All patients (n = 350)
Male patients
(n = 193)
Female patients
(n = 157)
(median)
Percentiles
th
th
(10 )
(90 )
Variable
Lost to follow-up (n = 141)
Male patients
(n = 73)
Female patients
(n = 68)
(median)
Percentiles
th
th
(10 )
(90 )
Background data
Birth weight (SDS)
-0.2
-1.5
1.0
-0.3
-1.6
0.8
MPH (SDS)
-0.2
-1.9
1.4
-1.0
-2.2
0.7
1.6
0.3
7.5
1.5
0.3
6.2
10.3
4.6
14.4
1.6
0.3
5.5
Max GH peak (g/L)
Age at tumour diagnosis (years)
Time between diagnosis and start
of GH therapy (years)
MPH, mid-parental height; WHI, weight-for-height index; SDS, standard deviation scores
Michael B Ranke - KIGS 10 Year Book, 1999
(2/6)
Auxological characteristics of KIGS patients
with CNS tumours near the pituitary region
All patients (n = 350)
Male patients
(n = 193)
Female patients
(n = 157)
(median)
Percentiles
th
th
(10 )
(90 )
Variable
Lost to follow-up (n = 141)
Male patients
(n = 73)
Female patients
(n = 68)
(median)
Percentiles
th
th
(10 )
(90 )
At start of GH therapy
Chronological age (years)
12.3
8.1
16.0
12.3
8.2
16.6
Bone age (years)
11.0
6.0
13.7
10.0
6.5
13.5
Height (SDS)
-1.9
-3.6
-0.3
-2.2
-4.1
-0.5
Height – MPH (SDS)
-1.7
-3.4
0.1
-1.5
-3.2
0.6
WHI (%)
112
92
Mean GH dose (IU/kg/week)
0.48
0.28
First-year height velocity (cm/year)
7.2
3.7
146
113
0.68
10.5
MPH, mid-parental height; WHI, weight-for-height index; SDS, standard deviation scores
Michael B Ranke - KIGS 10 Year Book, 1999
93
146
0.48
0.33
0.65
6.0
3.2
9.5
(3/6)
Auxological characteristics of KIGS patients
with CNS tumours near the pituitary region
All patients
(n = 350)
Male patients
(n = 193)
Lost to follow-up
(n = 141)
Female patients
(n = 157)
Male patients
(n = 73)
Percentile
(median)
th
Female patients
(n = 68)
Percentile
th
(10 )
(90 )
(median)
(10th)
(90th)
Last visit
Chronological age (years)
16.0
11.6
19.7
15.8
12.2
19.8
Height (SDS)
-1.1
-2.7
0.5
-1.6
-3.2
-0.2
Height – MPH (SDS)
-0.9
-2.4
0.9
-0.8
-2.4
0.9
WHI (%)
113
92
152
113
92
146
Mean GH dose (IU/kg/week)
0.47
0.31
0.69
0.46
0.33
0.64
Duration of GH therapy (years)
3.2
0.7
6.6
3.1
0.5
6.8
Height (SDS)
0.6
-0.3
2.2
0.4
-6.0
2.2
MPH, mid-parental height; WHI, weight-for-height index; SDS, standard deviation scores
Michael B Ranke - KIGS 10 Year Book, 1999
Auxological characteristics of KIGS patients
with CNS tumours near the pituitary region
GH therapy ongoing
(n = 100)
Final visit
(n = 109)
Male patients Female patients Male patients
(n = 58)
(n = 42)
(n = 62)
Female patients
(n = 47)
Percentile
Percentile
th
th
(median)
(10 )
(90 )
(median)
(10th)
(90th)
Birth weight (SDS)
-0.1
-1.3
1.3
-0.2
-1.6
1.0
MPH (SDS)
0.2
-1.3
1.4
0.1
-1.6
1.6
Max GH peak (g/L)
1.9
0.3
8.7
1.9
0.5
6.5
Background data
Age at tumour diagnosis
(years)
Time between diagnosis at
start of GH therapy (years)
MPH, mid-parental height; WHI, weight-for-height index; SDS, standard deviation scores
Michael B Ranke - KIGS 10 Year Book, 1999
(4/6)
Auxological characteristics of KIGS patients
with CNS tumours near the pituitary region
GH therapy ongoing
(n = 100)
Final visit
(n = 109)
Male patients Female patients Male patients
(n = 58)
(n = 42)
(n = 62)
Female patients
(n = 47)
Percentile
Percentile
th
th
(median)
(10 )
(90 )
(median)
(10th)
(90th)
Chronological age (years)
11.3
6.2
14.4
13.0
9.0
16.5
Bone age (years)
10.4
2.5
13.6
11.5
6.5
13.8
Height (SDS)
-1.5
-3.3
0.2
-1.8
-3.3
-0.3
Height – MPH (SDS)
-1.8
-3.4
0.4
-1.8
-3.6
-0.3
At start of GH therapy
WHI (%)
113
93
Mean GH dose (IU/kg/week)
0.52
0.35
First-year height velocity
(cm/year)
8.3
5.5
153
0.71
11.6
108
89
142
0.43
0.26
0.67
7.1
3.5
10.3
MPH, mid-parental height; WHI, weight-for-height index; SDS, standard deviation scores
Michael B Ranke - KIGS 10 Year Book, 1999
(5/6)
Auxological characteristics of KIGS patients
with CNS tumours near the pituitary region
GH therapy ongoing
(n = 100)
Final visit
(n = 109)
Male patients Female patients Male patients
(n = 58)
(n = 42)
(n = 62)
Female patients
(n = 47)
Percentile
Percentile
Variable
th
th
(median)
(10 )
(90 )
(median)
(10th)
(90th)
Chronological age (years)
14.4
9.7
18.0
16.9
13.7
20.2
Height (SDS)
-0.8
-2.2
1.1
-0.7
-2.7
0.7
Height – MPH (SDS)
-1.1
-2.4
1.3
-0.9
-2.6
0.7
Last visit
WHI (%)
112
93
150
112
92
157
Mean GH dose (IU/kg/week)
0.52
0.39
0.72
0.44
0.27
0.73
Duration of GH therapy
2.8
0.4
6.2
3.6
1.2
6.6
Height (SDS)
0.6
-0.1
2.4
1.0
-0.2
2.2
MPH, mid-parental height; WHI, weight-for-height index; SDS, standard deviation scores
Michael B Ranke - KIGS 10 Year Book, 1999
(6/6)
(1/6)
Auxological characteristics of KIGS patients
with CNS tumours distant from the pituitary region
All patients (n = 820)
Male
patients
(n = 500)
Female patients
(n = 320)
Lost of follow-up (n = 214)
Male patients
(n = 121)
Percentiles
Variables
th
Female patients
(n = 93)
Percentiles
(median)
(10 )
th
(90 )
(median)
(10 )
th
(90 )
th
-0.2
0.1
4.1
5.1
3.9
-1.6
-1.4
1.0
1.6
1.5
1.2
1.5
11.0
10.7
8.0
-0.4
-0.1
3.9
-1.6
-1.7
1.0
1.1
1.3
10.5
Background data
Birth weight (SDS)
MPH (SDS)
Max GH peak (g/L)
Age at tumour diagnosis (years)
Time between diagnosis and
start of GH therapy (years)
MPH, mid-parental height; WHI, weight-for-height index; SDS, standard deviation scores
Michael B Ranke - KIGS 10 Year Book, 1999
(2/6)
Auxological characteristics of KIGS patients
with CNS tumours distant from the pituitary region
All patients (n = 820)
Male
patients
(n = 500)
Female patients
(n = 320)
Lost of follow-up (n = 214)
Male patients
(n = 121)
Percentiles
Variables
Female patients
(n = 93)
Percentiles
(median)
(10th)
(90th)
(median)
(10th)
(90th)
10.1
9.0
-1.4
-1.5
108
0.54
7.8
6.3
4.2
-2.9
-3.1
91
0.35
4.6
13.9
13.0
0.2
0.1
132
0.75
10.7
9.9
8.4
-1.9
-1.6
108
0.55
7.7
6.1
3.9
-3.3
-3.5
89
0.36
4.0
13.8
12.8
-0.1
0.1
127
0.73
10.6
At start of GH therapy
Chronological age (years)
Bone age (years)
Height (SDS)
Height – MPH (SDS)
WHI (%)
Mean GH dose (IU/kg/week)
First-year height velocity (cm/yr)
MPH, mid-parental height; WHI, weight-for-height index; SDS, standard deviation scores
Michael B Ranke - KIGS 10 Year Book, 1999
(3/6)
Auxological characteristics of KIGS patients
with CNS tumours distant from the pituitary region
All patients (n = 820)
Male
patients
(n = 500)
Female patients
(n = 320)
Lost of follow-up (n = 214)
Male patients
(n = 121)
Percentiles
Variables
Female patients
(n = 93)
Percentiles
(median)
(10th)
(90th)
(median)
(10th)
(90th)
14.1
-1.0
-1.0
110
0.55
3.4
0.3
9.6
-2.8
-2.9
91
0.37
0.8
-0.7
17.7
0.7
0.6
139
0.75
7.1
1.5
13.2
-1.4
-1.1
107
0.53
2.8
0.4
8.51
-2.9
-3.1
88
0.28
0.6
-0.4
17.6
0.5
0.6
135
0.75
6.1
1.7
Last visit
Chronological age (years)
Height (SDS)
Height – MPH (SDS)
WHI (%)
Mean GH dose (IU/kg/week)
Duration of GH therapy (years)
Height (SDS)
MPH, mid-parental height; WHI, weight-for-height index; SDS, standard deviation scores
Michael B Ranke - KIGS 10 Year Book, 1999
(4/6)
Auxological characteristics of KIGS patients
with CNS tumours distant from the pituitary region
GH therapy ongoing
(n = 313)
Male patients
(n = 186)
Female patients
(n = 127)
Final visit (n = 293)
Male patients
(n = 193)
Percentiles
Variables
Female patients
(n = 100)
Percentiles
(median)
(10 )
th
(90 )
(median)
(10 )
th
(90 )
-0.1
0.3
4.5
-1.7
-1.1
0.9
1.1
1.7
12.4
-0.1
0.0
4.1
-1.6
-1.4
1.0
1.2
1.5
10.1
th
th
Background data
Birth weight (SDS)
MPH (SDS)
Max GH peak (g/L)
Age at tumour diagnosis (years)
Time between diagnosis and
start of GH therapy (years)
MPH, mid-parental height; WHI, weight-for-height index; SDS, standard deviation scores
Michael B Ranke - KIGS 10 Year Book, 1999
(5/6)
Auxological characteristics of KIGS patients
with CNS tumours distant from the pituitary region
All patients (n = 313)
Male patients
(n = 186)
Female patients
(n = 127)
Final visit (n = 293)
Male patients
(n = 193)
Female patients
(n = 100)
Percentiles
Variables
Percentiles
(median)
(10th)
(90th)
(median)
(10th)
(90th)
9.1
8.0
-1.2
-1.5
106
0.57
8.4
5.5
3.8
-2.6
-3.0
92
-0.43
5.8
13.0
12.5
0.3
-0.1
133
0.77
10.8
10.9
10.0
-1.4
-1.1
108
0.49
7.3
7.5
5.8
-2.8
-2.9
92
-0.3
4.6
14.4
14.3
0.2
0.1
134
0.72
10.2
At start of GH therapy
Chronological age (years)
Bone age (years)
Height (SDS)
Height – MPH (SDS)
WHI (%)
Mean GH dose (IU/kg/week)
First-year height velocity (cm/yr)
MPH, mid-parental height; WHI, weight-for-height index; SDS, standard deviation scores
Michael B Ranke - KIGS 10 Year Book, 1999
(6/6)
Auxological characteristics of KIGS patients
with CNS tumours distant from the pituitary region
All patients (n = 313)
Male patients
(n = 186)
Final visit (n = 293)
Female patients
(n = 127)
Male patients
(n = 193)
Percentiles
Variables
th
th
Female patients
(n = 100)
Percentiles
(median)
(10 )
(90 )
(median)
12.7
-0.5
-0.9
110
0.58
2.8
0.5
8.7
-2.2
-2.4
91
0.43
0.6
-0.3
16.0
1.0
0.7
138
0.74
6.7
1.6
16.0
-1.2
-1.1
112
0.53
4.4
0.1
(10 )
th
(90 )
th
12.9
-3.0
-3.0
92
0.33
1.5
-1.0
18.3
0.5
0.5
146
0.77
8.3
1.3
Last visit
Chronological age (years)
Height (SDS)
Height – MPH (SDS)
WHI (%)
Mean GH dose (IU/kg/week)
Duration of GH therapy (years)
Height (SDS)
MPH, mid-parental height; WHI, weight-for-height index; SDS, standard deviation scores
Michael B Ranke - KIGS 10 Year Book, 1999
Pituitary deficits in KIGS patients with CNS tumours
Near pituitary
Distant from pituitary
Pituitary deficit
(n)
(%)
(n)
(%)
Thyroid-stimulating hormone
174
50
190
23
Adrenocorticotrophic hormone
155
44
69
8
Luteinising hormone/folliclestimulating hormone
Anti-diuretic hormone
121
35
58
7
176
50
49
6
Michael B Ranke - KIGS 10 Year Book, 1999
Chronological age (years) at onset of
puberty in adolescents with CNS tumours
Female patients
Male patients
(10th-90th
percentile)
(n)
(median)
13.2
8.7-15.8
19
13.1
9.4-17.1
35
14.4
12.4-17.3
42
15.6
13.9-18.1
Spontaneous puberty
53
10.3
9.1-13.7
83
11.8
9.9-14.2
Induced puberty
18
14.2
11.6-16.4
19
14.9
12.2-17.6
(n)
(median)
Spontaneous puberty
24
Induced puberty
Group
(10th-90th
percentile)
Tumour near pituitary
Tumour distant from
pituitary
Michael B Ranke - KIGS 10 Year Book, 1999
(1/8)
Auxological characteristics of KIGS patients
from tumour subgroups
Germinoma
(n=185)
(MPHD=91%)
(m=93)
Variable
(median)
Medulloblastoma
(n=350)
(MPHD=54%)
(f=92) (m=231)
(f=119)
Percentiles
Percentiles
(10th)
(90th) (median) (10th) (90th)
Astrocytoma
(n=130)
(MPHD=54%)
(m=77)
(f=53)
Percentiles
(median) (10th) (90th)
Background data
Birth weight (SDS)
-0.2
-1.3
1.0
-0.1
-1.6
1.1
-0.3
-2.0
1.3
MPH (SDS)
-0.5
-2.1
1.3
0.1
-1.4
1.6
0.1
-1.2
1.7
1.5
0.3
6.1
4.9
1.4
12.5
3.1
0.7
11.0
Age at tumour diagnosis (years)
10.7
6.8
14.2
5.4
1.9
10.5
5.1
1.5
10.1
Time between diagnosis and GH
start (years)
1.6
0.5
5.0
3.5
1.8
6.8
4.5
1.7
8.0
Max GH peak (g/L)
MPHD, multiple pituitary hormone deficits; m, male; f, female; WHI, weight-for-height index; SDS,
standard deviation scores
Michael B Ranke - KIGS 10 Year Book, 1999
(2/8)
Auxological characteristics of KIGS patients
from tumour subgroups
Germinoma
(n=185)
(MPHD=91%)
(m=93)
Variable
(median)
Medulloblastoma
(n=350)
(f=92)
(m=231)
Percentiles
(10th)
(90th)
(median)
(MPHD=54%)
(f=119)
Percentiles
(10th)
(90th)
Astrocytoma
(n=130)
(MPHD=54%)
(m=77)
(f=53)
(median)
Percentiles
(10th) (90th)
At start of GH therapy
Chronological age (years)
12.6
9.8
16.1
10.0
6.0
13.7
10.0
6.0
14.0
Bone age (years)
11.0
7.3
13.9
9.3
3.9
13.0
9.1
5.1
13.0
Height (SDS)
-1.9
-3.7
-0.3
-1.4
-2.8
0.0
-1.1
-2.8
0.6
Height – MPH (SDS)
-1.5
-3.1
0.2
-1.5
-3.2
-0.2
-1.0
-2.9
0.4
WHI (%)
Mean GH dose (IU/kg/week)
111
0.48
92
0.29
143
0.65
105
0.56
91
0.36
128
112
0.76
MPHD, multiple pituitary hormone deficits; m, male; f, female; WHI, weight-for-height index; SDS,
standard deviation scores
Michael B Ranke - KIGS 10 Year Book, 1999
0.54
92
0.32
141
0.72
(3/8)
Auxological characteristics of KIGS patients
from tumour subgroups
Germinoma
(n=185)
(MPHD=91%)
(m=93)
Variable
(median)
Medulloblastoma
(n=350)
(MPHD=54%)
(f=92) (m=231)
(f=119)
Percentiles
Percentiles
th
th
(10 )
(90 ) (median) (10th) (90th)
Astrocytoma
(n=130)
(MPHD=54%)
(m=77)
(f=53)
Percentiles
(median) (10th) (90th)
First year
Height (SDS)
0.2
-0.2
0.8
0.3
-0.1
0.7
0.5
-0.1
1.1
Height velocity (cm/year)
6.7
3.5
9.9
7.4
4.6
9.8
8.5
4.4
11.9
Studentised residuals
-0.1
-1.5
1.4
-0.9
-2.2
0.1
0.1
-1.0
1.5
MPHD, multiple pituitary hormone deficits; m, male; f, female; WHI, weight-for-height index; SDS, standard deviation scores
Michael B Ranke - KIGS 10 Year Book, 1999
(4/8)
Auxological characteristics of KIGS patients
from tumour subgroups
Germinoma
(n=185)
(MPHD=91%)
(m=93)
Variable
(median)
Medulloblastoma
(n=350)
(f=92)
(m=231)
Percentiles
(10th)
(90th)
(median)
(MPHD=54%)
(f=119)
Percentiles
(10th)
(90th)
Astrocytoma
(n=130)
(MPHD=54%)
(m=77)
(f=53)
(median)
Percentiles
(10th) (90th)
Last visit
Chronological age (years)
16.4
12.8
19.8
14.4
9.9
17.5
13.8
9.2
17.2
Height (SDS)
-1.2
-2.9
0.2
-1.2
-3.0
0.3
-0.3
-2.6
1.6
Height – MPH (SDS)
-0.8
-2.4
0.8
-1.4
-3.1
0.2
-0.5
-2.3
1.2
WHI (%)
113
93
150
111
91
135
111
89
140
Mean GH dose (IU/kg/week)
0.45
0.30
0.65
0.58
0.41
0.77
0.52
0.33
0.72
Duration of GH therapy (years)
3.2
0.7
3.5
3.6
0.9
7.7
3.1
0.6
6.4
Height (SDS)
0.6
-0.4
2.2
0.1
-0.8
1.1
0.7
-0.4
1.9
MPHD, multiple pituitary hormone deficits; m, male; f, female; WHI, weight-for-height index; SDS, standard deviation scores
Michael B Ranke - KIGS 10 Year Book, 1999
(5/8)
Auxological characteristics of KIGS patients
from tumour subgroups
Ependynoma
(n=80)
(MPHD=52%)
(m=49)
Variable
(median)
Glioma
(f=31)
Percentiles
(10th)
(90th)
Nasopharyngeal
(n=115)
(MPHD=63%)
(n=27)
(MPHD=54%)
(m=58)
(f=57)
(m=17)
(f=10)
(median)
Percentiles
(10th)
(90th)
(median)
Percentiles
(10th) (90th)
Background data
Birth weight (SDS)
-0.2
-1.6
1.1
-0.3
-1.6
1.1
0.0
-1.6
1.8
MPH (SDS)
0.4
-1.1
2.0
0.0
-1.6
1.5
0.5
-0.8
2.1
Max GH peak (g/L)
4.3
1.5
11.0
3.2
0.6
9.9
3.5
1.0
11.0
Age at tumour diagnosis (years)
4.5
2.0
9.4
5.0
1.2
10.4
5.6
2.4
11.1
Time between diagnosis and
GH start (years)
3.9
1.7
9.3
4.2
1.4
7.9
4.2
2.0
8.0
MPHD, multiple pituitary hormone deficits; m, male; f, female; WHI, weight-for-height index; SDS, standard deviation scores
Michael B Ranke - KIGS 10 Year Book, 1999
(6/8)
Auxological characteristics of KIGS patients
from tumour subgroups
Ependynoma
(n=80)
(MPHD=52%)
(m=49)
Variable
(median)
Glioma
(f=31)
Percentiles
(10th)
(90th)
Nasopharyngeal
(n=115)
(MPHD=63%)
(n=27)
(MPHD=54%)
(m=58)
(f=57)
(m=17)
(f=10)
(median)
Percentiles
(10th)
(90th)
(median)
Percentiles
(10th) (90th)
At start of GH therapy
Chronological age (years)
9.7
6.6
13.0
9.7
6.1
14.1
10.1
7.7
14.9
Bone age (years)
8.5
5.0
13.2
10.0
4.5
14.1
8.5
6.1
13.5
Height (SD)
-1.2
-2.7
-0.2
-1.3
-3.2
0.9
-1.5
-2.8
-0.3
Height – MPH (SDS)
-1.6
-3.6
-0.2
-1.2
-3.2
1.1
-1.8
-3.9
-0.9
WHI (%)
Mean GH dose (IU/kg/week)
107
0.55
92
0.40
131
0.76
114
0.51
97
0.30
142
0.77
98
0.56
MPHD, multiple pituitary hormone deficits; m, male; f, female; WHI, weight-for-height index; SDS,
standard deviation scores
Michael B Ranke - KIGS 10 Year Book, 1999
89
0.45
124
0.8
(7/8)
Auxological characteristics of KIGS patients
from tumour subgroups
Ependynoma
(n=80)
(MPHD=52%)
(m=49)
Variable
(median)
Glioma
(f=31)
Nasopharyngeal
(n=115)
(MPHD=63%)
(n=27)
(MPHD=54%)
(m=58)
(f=57)
(m=17)
(f=10)
Percentiles
Percentiles
(10th)
(90th) (median) (10th) (90th)
Percentiles
(median) (10th) (90th)
First year
Height (SDS)
0.5
0.0
0.9
0.4
-0.2
1.1
0.5
0.0
0.8
Height velocity (cm/year)
8.3
4.9
10.8
8.0
4.9
11.4
8.8
4.9
10.1
-0.2
-2.2
1.0
-0.3
-1.2
1.0
Studentised residuals
MPHD, multiple pituitary hormone deficits; m, male; f, female; WHI, weight-for-height index; SDS, standard deviation scores
Michael B Ranke - KIGS 10 Year Book, 1999
(8/8)
Auxological characteristics of KIGS patients
from tumour subgroups
Ependynoma
(n=80)
(MPHD=52%)
(m=49)
Variable
(median)
Glioma
(f=31)
Nasopharyngeal
(n=115)
(MPHD=63%)
(n=27)
(MPHD=54%)
(m=58)
(f=57)
(m=17)
(f=10)
Percentiles
Percentiles
(10th)
(90th) (median) (10th) (90th)
Percentiles
(median) (10th) (90th)
Last visit
Chronological age (years)
13.4
8.5
17.7
14.1
8.2
18.2
14.0
10.2
17.8
Height (SDS)
-0.9
-2.7
0.6
-0.5
-2.2
1.3
-1.1
-2.1
0.7
Height – MPH (SDS)
-1.3
-3.4
0.6
-0.5
-2.2
1.1
-1.6
-3.6
0.1
115
97
WHI (%)
107
93
140
152
Mean GH dose (IU/kg/week)
0.56
0.41
0.8s
0.52
0.33
0.7
0.58
0.46
0.77
Duration of GH therapy (years)
2.9
1.0
6.9
3.1
0.8
7.1
3.4
0.7
6.0
Height (SDS)
0.5
-0.7
1.4
0.6
-0.5
2.0
MPHD, multiple pituitary hormone deficits; m, male; f, female; WHI, weight-for-height index; SDS, standard deviation scores
Michael B Ranke - KIGS 10 Year Book, 1999
Studentised residuals
Response to GH treatment compared with predicted height
velocity (cm/year) shown as studentised residuals for the first
prepubertal year for patients with CNS tumours distant from the
pituitary basedon the KIGS prediction model for idiopathic GHD
Predicted height velocity (cm/year)
Michael B Ranke - KIGS 10 Year Book, 1999
(1/2)
Studentised residuals
Response to GH treatment compared with predicted height
velocity (cm/year) shown as studentised residuals for the first
prepubertal year for patients with medulloblastoma based on the KIGS
prediction model for idiopathic GHD
Predicted height velocity (cm/year)
Michael B Ranke - KIGS 10 Year Book, 1999
(2/2)
(1/4)
Comparison of final height data of patients
with germinoma and medulloblastoma
Germinoma
(n=25)
(MPHD=96%)
(m=6)
(f=19)
Medulloblastoma
(n=26)
(MPHD=69%)
(m=17)
(f=9)
Percentiles
(10th)
(90th)
Percentiles
(median) (10th) (90th)
(median)
Background data
MPH (SDS)
Age at tumour diagnosis (years)
Time between diagnosis and GH start
(years)
0.1
-2.1
1.7
0.0
-1.0
1.8
10.2
7.1
14.0
8.0
2.6
9.5
1.3
0.2
4.5
3.7
1.4
6.2
MPHD, multiple pituitary hormone deficits; m, male; f, female; MPH, mid-parental height; SDS, standard deviation scores
Michael B Ranke - KIGS 10 Year Book, 1999
(2/4)
Comparison of final height data of patients
with germinoma and medulloblastoma
Germinoma
(n=25)
(MPHD=96%)
(m=6)
(f=19)
Medulloblastoma
(n=26)
(MPHD=69%)
(m=17)
(f=9)
Percentiles
(10th)
(90th)
Percentiles
(median) (10th) (90th)
(median)
At start of GH therapy
Chronological age (years)
12.2
10.1
14.5
10.1
7.6
12.9
Height (SDS)
-2.1
-3.3
-1.1
-2.0
-2.8
0.5
Height – MPH (SDS)
-2.0
-3.3
-0.1
-2.0
-3.2
-0.6
Mean GH dose (IU/kg/week)
0.50
0.29
0.65
0.50
0.31
MPHD, multiple pituitary hormone deficits; m, male; f, female; MPH, mid-parental height; SDS,
standard deviation scores
Michael B Ranke - KIGS 10 Year Book, 1999
0.78
(3/4)
Comparison of final height data of patients
with germinoma and medulloblastoma
Germinoma
(n=25)
(MPHD=96%)
(m=6)
(f=19)
Medulloblastoma
(n=26)
(MPHD=69%)
(m=17)
(f=9)
Percentiles
(10th)
(90th)
Percentiles
(median) (10th) (90th)
(median)
First year
Height (SDS)
0.1
-0.3
0.6
0.2
0.0
0.7
Height velocity (cm/year)
7.1
2.7
8.9
6.2
5.1
9.3
-1.1
-2.7
0.9
Studentised residuals
MPHD, multiple pituitary hormone deficits; m, male; f, female; MPH, mid-parental height; SDS, standard deviation scores
Michael B Ranke - KIGS 10 Year Book, 1999
(4/4)
Comparison of final height data of patients
with germinoma and medulloblastoma
Germinoma
(n=25)
(MPHD=96%)
(m=6)
(f=19)
Medulloblastoma
(n=26)
(MPHD=69%)
(m=17)
(f=9)
Percentiles
(10th)
(90th)
Percentiles
(median) (10th) (90th)
(median)
Last year
Chronological age (years)
18.5
16.3
20.7
17.6
15.3
19.4
Height (SDS)
-1.0
-2.6
0.9
-2.7
-5.0
0.2
Height MPH (SDS)
-1.0
-1.9
0.4
-2.3
-4.8
-0.9
Mean GH dose (IU/kg/week)
0.47
0.34
0.66
0.58
0.38
0.79
Duration of GH therapy (years)
5.5
3.0
8.7
8.3
5.5
10.5
Height (SDS)
0.7
0.1
2.3
-0.5
-2.0
0.6
-0.2
-0.5
1.5
-0.8
-1.0
-0.5
Height (SDS) in puberty
MPHD, multiple pituitary hormone deficits; m, male; f, female; MPH, mid-parental height; SDS,
standard deviation scores
Michael B Ranke - KIGS 10 Year Book, 1999